alisporivir (Debio 025)
Debio 025 (alisporivir) is the first in a new class of drugs called cyclophilin inhibitors, with a potential in a wide range of therapeutic indications. Alisporivir was first thoroughly investigated for its antiviral properties in hepatitis C and HIV patients and consequently benefits from a large safety and efficacy database.
Pre-clinical in vitro research from the Mondor Institute of Biomedical Research (INSERM U955) has shown evidence for the effectiveness of alisporivir against the replication of SARS-COV-2 (COVID-19). Alisporivir is currently tested in a phaseII study conducted in France by the AP-HP (Greater Paris University Hospitals) to assess the efficacy and safety of the compound.
Today, our development efforts are focused on non-viral diseases where cylophilins play a key role in regulating cell death pathways and we strive to generate compelling evidence supporting further clinical investigations in patients with high unmet medical needs.